---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-040539"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:13:02.268865+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ADMA Q3 revenue $134.2M (+12% YoY); raises FY25 revenue guidance to $510M+, FY26 to $630M+

## Summary
- GAAP net income $36.4M (+1% YoY); adjusted EBITDA $58.7M (+29% YoY).
- Revenue guidance raised: FY25 to ≥$510M (from >$500M); FY26 to ≥$630M (from >$625M).
- Adj EBITDA guidance: FY25 reaffirmed at $235M; FY26 raised to >$355M (from >$340M).
- FDA lot release of first yield-enhanced batches; gross margin expansion expected from Q4 2025.
- Record ASCENIV demand; real-world data shows >50% infection reduction (2.1→0.9/year).

## SEC filing metadata
- accession: 0001140361-25-040539
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036125040539/0001140361-25-040539-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036125040539/ef20058354_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-040539
- JSON: https://secwatch.observer/filing/0001140361-25-040539.json
- Plain text: https://secwatch.observer/filing/0001140361-25-040539.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.